Skip to main content
Signal8
Launch Terminal

LIGAND PHARMACEUTICALS INC (LGND)

Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Ligand Pharmaceuticals Incorporated logo

Ligand Pharmaceuticals Incorporated

NASDAQ:LGNDHealthcare
+1.71%$322.75
AH$324.00+0.39%vs close
Mkt Cap$6.46B
Float18.88M
O/S20M
Vol
$ Vol
RVOL
Inst Own-
SI13.3%
Earnings
Dilution
Ligand Pharmaceuticals Incorporated logoNASDAQ:LGND$322.75+1.71%
Upcoming Catalysts
Phase Distribution
21 lead-sponsored trials·0 active·19 completed
Phase 13
Phase 1/21
Phase 215
Phase 32
(20 more as collaborator)

Trials need funding. See this company's dilution risk and cash position.

Recent Deals
  • AvenCell Therapeutics, Inc.COLLAB
    / $47M totalSep 24, 2026
    AVC-201AVC-203
  • AvenCell Therapeutics, Inc.COLLAB
    $47M upfrontSep 24, 2026
    AVC-201AVC-203
  • SydnexisMILESTONE
    $23M upfrontSep 22, 2026
    Ryjunea
Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Completed

    Postmenopausal Evaluation and Risk-reduction With Lasofoxifene (PEARL)

    lasofoxifene, lasofoxifene

    Osteoporosis

    Enrollment
    8,556
    Start
    Nov 2001
    Primary Completion
    Dec 2007
    Completion
    Dec 2007
    NCT00141323
  • Phase 3
    Completed

    Comparison of Raloxifene and Lasofoxifene - A Randomized, Blinded Study of These Drugs and Placebo on Bone Loss

    lasofoxifene, raloxifene

    Osteoporosis

    Enrollment
    540
    Start
    May 2003
    Primary Completion
    Oct 2005
    Completion
    Oct 2005
    NCT00163137
  • Phase 2
    Completed

    A Study of Targretin Capsules in Patients With AIDS-Related Kaposi's Sarcoma

    Bexarotene

    Sarcoma, Kaposi, HIV Infections

    Enrollment
    27
    Start
    -
    Primary Completion
    -
    Completion
    -
    NCT00002212
  • Phase 2
    Completed

    Bexarotene in Treating Patients With Metastatic Breast Cancer

    bexarotene

    Breast Cancer

    Enrollment
    180
    Start
    Oct 1998
    Primary Completion
    -
    Completion
    Mar 2003
    NCT00003752
  • Phase 2
    Completed

    Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma

    denileukin diftitox, dexamethasone

    Drug/Agent Toxicity by Tissue/Organ, Lymphoma

    Enrollment
    -
    Start
    Nov 1999
    Primary Completion
    -
    Completion
    Mar 2004
    NCT00006345
  • Phase 2
    Completed

    Dose Response Study of Lasofoxifene in Postmenopausal Women With Osteoporosis - Japanese Asian Dose Evaluation

    lasofoxifene, Placebo

    Osteoporosis

    Enrollment
    497
    Start
    Jun 2004
    Primary Completion
    Mar 2006
    Completion
    Mar 2006
    NCT00143273
  • Phase 2
    Completed

    Safety, Tolerability, and Efficacy Study of MB07803 Administered to Patients With Type 2 Diabetes Mellitus

    MB07803, Placebo

    Type 2 Diabetes Mellitus

    Enrollment
    105
    Start
    Mar 2007
    Primary Completion
    Mar 2008
    Completion
    Mar 2008
    NCT00458016
  • Phase 2
    Completed

    A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat Hypertension

    PS433540, placebo

    Hypertension

    Enrollment
    280
    Start
    Aug 2007
    Primary Completion
    Apr 2008
    Completion
    May 2008
    NCT00522925
  • Phase 2
    Completed

    The Effects of Aplindore on the Treatment of Signs and Symptoms of Parkinson's Disease

    Aplindore, Placebo

    Early Stage Parkinson's Disease

    Enrollment
    40
    Start
    Jan 2008
    Primary Completion
    Jul 2008
    Completion
    -
    NCT00623324
  • Phase 2
    Completed

    The Effects of Aplindore on the Treatment of Signs and Symptoms of Restless Legs Syndrome

    Aplindore, Placebo

    Restless Legs Syndrome

    Enrollment
    24
    Start
    Feb 2008
    Primary Completion
    Oct 2008
    Completion
    -
    NCT00626418
  • Phase 2
    Completed

    A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With Hypertension

    irbesartan, placebo

    Hypertension

    Enrollment
    261
    Start
    Mar 2008
    Primary Completion
    Nov 2008
    Completion
    Dec 2008
    NCT00635232
  • Phase 2
    Completed

    The Prevention Of Postmenopausal Osteoporosis With Lasofoxifene And Cytokine Evaluation

    Lasofoxifene

    Bone Loss

    Enrollment
    51
    Start
    Sep 2004
    Primary Completion
    -
    Completion
    Sep 2007
    NCT00674453
  • Phase 2
    Withdrawn

    Study of MB07811 in Subjects With Hypercholesterolemia

    MB07811, Placebo

    Hypercholesterolemia

    Enrollment
    80
    Start
    Apr 2009
    Primary Completion
    Dec 2009est.
    Completion
    Dec 2009est.
    NCT00879112
  • Phase 2
    Completed

    Compare CE-Budesonide Nasal Solution & Rhinocort Aqua in an EEC Study of AR

    Budesonide, Placebo

    Seasonal Allergic Rhinitis

    Enrollment
    65
    Start
    Feb 2007
    Primary Completion
    Apr 2007
    Completion
    Apr 2007
    NCT00938613
  • Phase 2
    Completed

    Compare Captisol-Enabled (CE) Budesonide + Azelastine Nasal Solution and Rhinocort Aqua + Astelin in an Environmental Exposure Chamber (EEC) Study of Allergic Rhinitis

    Budesonide + Azelastine, Budesonide + Azelastine

    Seasonal Allergic Rhinitis

    Enrollment
    108
    Start
    Feb 2008
    Primary Completion
    May 2008
    Completion
    May 2008
    NCT00940953
  • Phase 2
    Completed

    A Study of LGD-6972 in Patients With Type 2 Diabetes Mellitus

    LGD-6972-5 mg, LGD-6972-10 mg

    Type 2 Diabetes Mellitus

    Enrollment
    148
    Start
    Sep 2016
    Primary Completion
    Jun 2017
    Completion
    Jun 2017
    NCT02851849
  • Phase 2
    Withdrawn

    Comparison of Captisol-Enabled™ Iohexol and Omnipaque™ in Patients With Impaired Renal Function Undergoing Coronary Angiography

    CE-Iohexol, Iohexol

    Contrast-induced Nephropathy

    Enrollment
    0
    Start
    Jan 2022est.
    Primary Completion
    Mar 2023est.
    Completion
    Apr 2023est.
    NCT04627831
  • Phase 1/2
    Completed

    Safety and Tolerability of I.V. Infusion of MB07133 in Patients With Unresectable Hepatocellular Carcinoma

    MB07133 300mg/m2/day, MB07133 600 mg/m2/day

    Hepatocellular Carcinoma

    Enrollment
    28
    Start
    Sep 2003
    Primary Completion
    Jul 2007
    Completion
    -
    NCT00073736
  • Phase 1
    Completed

    Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LGD-6972 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus

    LGD-6972, Placebo (Captisol®)

    Type 2 Diabetes Mellitus

    Enrollment
    56
    Start
    Nov 2013
    Primary Completion
    Feb 2014
    Completion
    Mar 2014
    NCT01919684
  • Phase 1
    Completed

    Safety and Tolerability Study of Oral LGD-6972 for Type 2 Diabetes Mellitus

    LGD-6972, Placebo (Captisol ®)

    Type 2 Diabetes Mellitus

    Enrollment
    48
    Start
    Oct 2014
    Primary Completion
    May 2015
    Completion
    Jun 2015
    NCT02250222
  • Phase 1
    Completed

    A Comparison Study of the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation

    LGD-6972 Solution, LGD-6972 Capsules

    Type 2 Diabetes Mellitus (T2DM)

    Enrollment
    12
    Start
    Feb 2016
    Primary Completion
    May 2016
    Completion
    May 2016
    NCT02672839
Search ClinicalTrials.gov for “Ligand Pharmaceuticals”